PMID- 29391775
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200929
IS  - 1177-5475 (Print)
IS  - 1177-5491 (Electronic)
IS  - 1177-5475 (Linking)
VI  - 12
DP  - 2018
TI  - Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin 
      America: impact of tumor necrosis factor-alpha inhibitors in clinical practice.
PG  - 1-9
LID - 10.2147/BTT.S148606 [doi]
AB  - Tumor necrosis factor-alpha (TNF-alpha) inhibitors are increasingly becoming the standard 
      of care for treating a number of inflammatory diseases. However, treatment with 
      TNF-alpha inhibitors carries an inherent risk of compromising the immune system, 
      resulting in an increased susceptibility to infections and malignancies. This 
      increased risk of infection is of particular concern in Asia, Eastern Europe, and 
      Latin America where tuberculosis (TB) and viral hepatitis are endemic. In this 
      brief review, we examine the literature and review the impact of TNF-alpha inhibitors 
      on the incidence and the reactivation of latent disease with respect to TB, 
      hepatitis C infection, and hepatitis B infection. Our findings show that TNF-alpha 
      inhibitors are generally safe, if used with caution. Patients should be screened 
      prior to the initiation of TNF-alpha inhibitor treatment and given prophylactic 
      treatment if needed. In addition, patients should be monitored during treatment 
      with TNF-alpha inhibitors and after treatment has stopped to ensure that infections, 
      if detected, are treated promptly and effectively. Our analysis is consistent 
      with other reports and guidelines.
FAU - Chen, Yi-Hsing
AU  - Chen YH
AD  - Division of Allergy, Immunology, and Rheumatology, Taichung Veterans General 
      Hospital, Taichung City, Taiwan.
FAU - de Carvalho, Hellen Mds
AU  - de Carvalho HM
AD  - Unidade de Reumatologia, Hospital de Base do Distrito Federal, Brasilia, Brazil.
FAU - Kalyoncu, Umut
AU  - Kalyoncu U
AD  - Department of Internal Medicine, Faculty of Medicine, Division of Rheumatology, 
      Hacettepe University, Ankara, Turkey.
FAU - Llamado, Lyndon John Q
AU  - Llamado LJQ
AD  - Pfizer, Makati City, Philippines.
FAU - Solano, Gaston
AU  - Solano G
AD  - Pfizer, San Jose, Costa Rica.
FAU - Pedersen, Ron
AU  - Pedersen R
AD  - Pfizer, Collegeville, PA, USA.
FAU - Lukina, Galina
AU  - Lukina G
AD  - Moscow Clinical Scientific Center, Moscow, Russia.
FAU - Lichauco, Juan J
AU  - Lichauco JJ
AD  - Section of Rheumatology, Department of Medicine, St. Luke's Medical Center, 
      Quezon City, Manila, Philippines.
FAU - Vasilescu, Radu S
AU  - Vasilescu RS
AD  - Pfizer, Brussels, Belgium.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180112
PL  - New Zealand
TA  - Biologics
JT  - Biologics : targets & therapy
JID - 101321511
PMC - PMC5769557
OTO - NOTNLM
OT  - hepatitis B
OT  - hepatitis C
OT  - reactivation
OT  - risk
OT  - tuberculosis
OT  - tumor necrosis factor inhibitors
COIS- Disclosure Y-HC is on the advisory boards of AbbVie, Astellas, Astra-Zeneca, 
      Bristol Myers Squibb, GlaxoSmithKline, Guigai, Inova Diagnostics, Johnson & 
      Johnson, Lilly, MSD, Novartis, Pfizer, Roche, and ThermoFisher Scientific and has 
      received funding for research and clinical trials from AbbVie, Boehringer 
      Ingelheim, Bristol Myers Squibb, Guigai, Johnson & Johnson, MSD, Novartis, 
      Pfizer, Roche, Sanofi, and UCB. HMDSdC is a consultant for AbbVie, AstraZeneca, 
      Janssen, Novartis, Pfizer, and Roche. UK is a consultant for AbbVie, BMS, MSD, 
      Pfizer, and UCB. LJQL, GS, RP, and RV are employees of Pfizer and own stock in 
      the company. JJL is on the advisory board of Pfizer. The authors report no other 
      conflicts of interest in this work.
EDAT- 2018/02/03 06:00
MHDA- 2018/02/03 06:01
PMCR- 2018/01/12
CRDT- 2018/02/03 06:00
PHST- 2018/02/03 06:00 [entrez]
PHST- 2018/02/03 06:00 [pubmed]
PHST- 2018/02/03 06:01 [medline]
PHST- 2018/01/12 00:00 [pmc-release]
AID - btt-12-001 [pii]
AID - 10.2147/BTT.S148606 [doi]
PST - epublish
SO  - Biologics. 2018 Jan 12;12:1-9. doi: 10.2147/BTT.S148606. eCollection 2018.